Junto Capital Management LP Acquires New Position in IQVIA Holdings Inc. $IQV

Key Points

• Junto Capital Management LP acquired a new position in IQVIA Holdings Inc., purchasing 200,213 shares valued at approximately $35.30 million during the first quarter.
• IQVIA reported quarterly earnings of $2.81 EPS, exceeding analysts' expectations, alongside a revenue of $4.02 billion, marking a 5.3% year-over-year increase.
• Over 89.62% of IQVIA's shares are owned by institutional investors, indicating strong institutional interest in the company.

Junto Capital Management LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 200,213 shares of the medical research company's stock, valued at approximately $35,298,000. Junto Capital Management LP owned about 0.12% of IQVIA at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Canada Pension Plan Investment Board grew its holdings in IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock valued at $810,069,000 after purchasing an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. lifted its position in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares during the last quarter. American Century Companies Inc. lifted its position in IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock valued at $253,695,000 after purchasing an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock valued at $251,852,000 after purchasing an additional 40,699 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of IQVIA by 13.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after buying an additional 167,057 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.2%

Shares of IQV traded up $0.31 during mid-day trading on Wednesday, hitting $184.05. 1,191,972 shares of the company's stock were exchanged, compared to its average volume of 1,932,363. The company has a market cap of $31.29 billion, a PE ratio of 26.64, a P/E/G ratio of 2.09 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $250.46. The company has a 50-day simple moving average of $178.24 and a 200 day simple moving average of $167.60. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the business earned $2.64 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. Robert W. Baird lifted their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Evercore ISI boosted their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Barclays increased their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, UBS Group upped their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.86.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.